Newron Pharmaceuticals SpA (NWRN) Stock Statistics & Valuation Metrics

Newron Pharmaceuticals SpA has a market cap or net worth of $128.93M. The enterprise value is CHF216.25M.

Newron Pharmaceuticals SpA has 19,958,858 shares outstanding. The number of shares has decreased by -2.65% in one year.

Newron Pharmaceuticals SpA’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Newron Pharmaceuticals SpA is -5.86. Newron Pharmaceuticals SpA’s PEG ratio is 0.82.

In the last 12 months, Newron Pharmaceuticals SpA had revenue of 9.06M and earned -16.22M in profits. Earnings per share was -0.91.

In the last 12 months, operating cash flow was -13.37M and capital expenditures -10.00K, giving a free cash flow of -13.38M billion.

Newron Pharmaceuticals SpA pays an annual dividend of ―, resulting in a dividend yield of ―

Newron Pharmaceuticals SpA upcoming earnings date is Sep 16, 2025, TBA Not Confirmed.

Newron Pharmaceuticals SpA as a current ratio of 0.68, with Debt / Equity ratio of -158.44%

In the past 12 months, Newron Pharmaceuticals SpA has paid 24.00K in taxes.

Newron Pharmaceuticals SpA EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Newron Pharmaceuticals SpA has $12.19M in cash and marketable securities with €16.89M in debt, giving a net cash position of $36.66M billion.

Gross margin is 100.00%, with operating margin of -128.40%, and net profit margin of -179.13%.

The average price target for Newron Pharmaceuticals SpA is ―, which is 11.43% higher than the current price. The consensus rating is ―